Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protein tyrosine phosphatase, non-receptor type 1 | Starlite/ChEMBL | References |
Homo sapiens | cell division cycle 25B | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1 uM | Inhibition of 6-His-N-terminal tagged human PTP1B expressed in Escherichia coli BL21 (DE3) cells assessed as pNP formation using pNPP as substrate incubated for 15 mins prior to substrate addition by plate reader analysis | ChEMBL. | 25938987 |
IC50 (binding) | = 13.7 uM | Inhibition of 6-His-N-terminal tagged human CDC-25B isoform 3 catalytic domain expressed in Escherichia coli BL21 (DE3) cells assessed as pNP formation using pNPP as substrate incubated for 15 mins prior to substrate addition by plate reader analysis | ChEMBL. | 25938987 |
IC50 (binding) | = 22 uM | Inhibition of full length 6-His-N-terminal tagged human LMW-PTP expressed in Escherichia coli BL21 (DE3) cells assessed as pNP formation using pNPP as substrate incubated for 15 mins prior to substrate addition by plate reader analysis | ChEMBL. | 25938987 |
Inhibition (binding) | Inhibition of 6-His-N-terminal tagged human PTP1B expressed in Escherichia coli BL21 (DE3) cells assessed as pNP formation using pNPP as substrate incubated for 15 mins prior to substrate addition by plate reader analysis in presence of 25 mM ammonium sulfate | ChEMBL. | 25938987 | |
Inhibition (binding) | Time-dependent inhibition of 6-His-N-terminal tagged human PTP1B expressed in Escherichia coli BL21 (DE3) cells using pNPP as substrate treated with compound prior to substrate addition by plate reader analysis | ChEMBL. | 25938987 | |
Inhibition (binding) | Mixed type of inhibition of 6-His-N-terminal tagged human PTP1B expressed in Escherichia coli BL21 (DE3) cells using pNPP as substrate by Lineweaver-Burk plot analysis | ChEMBL. | 25938987 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.